Dataset opportunity
Abilitypharma — 医疗影像数据集机会
Abilitypharma 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
67.3
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场规模预计将从 2024 年的 17.0 亿美元增长到 2034 年的 168.8 亿美元，年复合增长率为 25.8%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📝Published article
发表了胶质母细胞瘤模型中临床阶段药物疗效的研究
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Abilitypharma 持有一个高价值、跨司法管辖区的医疗影像数据集，模态为图像，来源于西班牙、美国、法国和以色列的临床试验。该精选数据集配有相应的病历和监管文件，为训练和验证强大的诊断人工智能算法提供了多样化的高质量数据。数据集的结构和相关文档使其可以直接应用于开发新颖的诊断工具。
该数据有望抓住蓬勃发展的医疗影像人工智能市场，该市场在 2024 年的估值为 17.0 亿美元，预计将以惊人的年复合增长率 25.8% 增长。[7] 虽然访问权限复杂——需要严格遵守 GDPR 关于患者健康信息的规定，进行跨司法管辖区的法律审查，并管理与专有研发数据相关的知识产权——但该数据集的稀有性和直接的临床相关性在该高增长领域提供了显著的竞争优势。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床试验数据涉及敏感的患者健康信息 (PHI)，需要严格遵守 GDPR；数据生成于多个国际地点（西班牙、美国、法国、以色列），需要跨司法管辖区的法律审查；专有研发数据与药物专利和知识产权保护相关。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Abilitypharma 持有一个来自已完成的IIb 期临床试验的专有医疗影像数据集，该试验涉及 140 名患有转移性胰腺癌的患者。对于诊断人工智能公司而言，这是一个难得的机会，可以获取高质量、结构化的数据，这些数据对于训练和验证针对特定、高需求肿瘤学适应症的算法至关重要。在全球医疗影像人工智能市场预计每年增长超过 25% 的情况下，该数据集为开发下一代诊断人工智能工具提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“病历”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
需求异常高，这得益于医疗影像人工智能市场的快速扩张，年复合增长率为 25.8%，从而产生了对高质量、经过临床验证的影像数据集的迫切需求。[7]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — 这家临床阶段的生物制药公司的核心业务是开发抗癌药物；其跨国临床试验的数据，包括医疗影像，是一个非常有价值的副产品，目前尚未出售。
- Deep Qualification80
⚠ 需要审查 — AbilityPharma 是一家生物制药公司，其核心业务是药物开发，而非数据销售。其产生的临床试验数据，包括医疗影像，是一个高价值的副产品。然而，由于其敏感的患者健康信息的性质，以及公司临床试验注册明确表示不计划共享个体参与者数据，该数据受到严格限制。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据指向一个来自已完成的IIb 期临床试验的结构化医疗影像数据集，为诊断人工智能开发者提供了一个针对特定癌症类型的稀有精选数据源。
Industrial data
这表明存在来自肿瘤学研究模型的临床前时间序列数据，对于开发预测药物疗效工具的人工智能公司来说很有价值。
Regulatory records
这些文本证据证实了持有者在开发针对肿瘤学未满足需求的药物方面的战略重点，提供了关键背景信息，验证了其数据资产的针对性和商业相关性。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Abilitypharma Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market size is expected to be worth around US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8% (source: Exactitude Consultancy). Investment score 67.3/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Nusindomarineservice — 工业运营数据集机会
View opportunity →工业Dornier Group — 维护日志数据集机会
View opportunity →其他P1Tennis — 传感器遥测数据集机会
View opportunity →